Navigation Links
Alimera Sciences Reports Fourth Quarter 2012 Financial Results
Date:3/21/2013

ATLANTA, March 21, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter ended December 31, 2012.

"We are about to begin the commercial launch of ILUVIEN®.  Product is in our European warehouse, and our distribution channels and commercial infrastructure are well positioned," said Dan Myers , president and chief executive officer of Alimera Sciences. "The training of our sales force has been completed and our teams are currently on the ground in Germany and the UK driving demand for ILUVIEN.  We will begin shipping as soon as we receive a required acceptance from the Medicine and Health products Regulatory Agency, on the intended commercial batch size.  Based on the increasing positive feedback we continue to receive, we believe that ophthalmologists in Europe are eager to prescribe ILUVIEN for their chronic DME patients who are considered insufficiently responsive to available therapies."

Market Access Update On January 23, 2013, Alimera announced that it had received final published guidance from the UK's National Institute of Health and Clinical Excellence (NICE), indicating that ILUVIEN is not a cost-effective treatment for chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. In response to this, Alimera submitted a simple patient access scheme (PAS) for ILUVIEN to the Patient Access Schemes Liaison Unit. The PAS has been agreed to by the UK's Department of Health and is now under consideration by NICE for inclusion in its rapid review facility. Under this facility, the Appraisal Commi
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
2. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
3. Alimera Sciences Names European Management Team
4. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
5. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
7. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
8. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
9. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
10. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
11. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Jan. 8, 2012  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today ... trial of its fully human monoclonal antibody against VEGF-C, ... The Phase 1 study will examine the safety ... with advanced solid tumours who have no other standard ...
... Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... founder and member of the Board of Directors, Wylie ... was a thoughtful leader with an incredible scientific mind ... by his terrific wit and disarming good nature.  He ...
Cached Medicine Technology:Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 2Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 3Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 4Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 5
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... December 15, 2014 OutMarket , ... released “ Social Media Cheat Sheets ,” a guide ... that drives results on the top ten social media ... It helps drive awareness, engagement, and customer service. It ... to make an impact on new networks and weather ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, 2014 ... millions of American women who have migraine: The debilitating headaches ... no association between migraine and breast cancer risk," said lead ... Medical School. "There is no positive association, so there is ... either." About 18 percent of American women and 6 ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... risk of deaths from advanced prostate cancer is to catch// ... suggests that effective screening can prevent as much as 35% ... in men and is the second leading cause of death ... cancers are discovered when they have already spread to other ...
... clinical trials support the enhanced bioavailability// of CoQ10 delivered ... manufacturers of CoQ10 products. ,Increasing its bioavailability, ... and food makers to use lower dosages, therefore saving ... food-grade emulsifiers and solvents to trap water droplets in ...
... to be able to block the HIV virus from entering human ... major step forward in treatment of HIV. ,Scientist from ... fight against the AIDS virus. The research headed by Hiroaki Mitsuya ... States. The patients took 0.02 ounces of AK602 twice a day ...
... A study done by the researchers of Ohio State University ... your diet, you tend to prosper as well. ,The ... gain are quite strong among white female population of America. ... lost weight, but this is not particularly true for black ...
... infants with lung problem are often treated with inhaled nitric ... that this therapy does not reduce the chances of death ... of opinion that premature babies who weigh less than 1.5kgs ... are the part of a study. Inhaled nitric oxide therapy ...
... and can be a cause of Global warming//. ... World’ said: ,"Worldwide reduction of meat production in the pursuit ... carry fewer political unknowns than cutting our consumption of fossil ... and chicken burgers would do more for the environment. ...
Cached Medicine News:Health News:Screening For Prostate Cancer May Reduce Mortality Rate 2
LM-770 Projection Digital Lensmeter...
Autolensmeter with color 5.7 inch LCD screen and built in printer....
Autolensmeter with black/white monitor and no internal printer....
An ideal basic fundus fluorescein camera with quality enhancing features at a mid-range price point. The camera has 1.7x magnification at 60 degree and 2.5x at 40 degree....
Medicine Products: